Communiqués Savara Inc.

Actions

SVRA

US8051111016

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
5,420 ^USD	+5,65%		+1,88%	-10,12%

24/08	Savara annonce de nouvelles présentations des résultats de l'essai clinique de phase 3 sur la solution d'inhalation de molgramostim dans la protéinose alvéolaire pulmonaire auto-immune lors du congrès 2026 de l'European Respiratory Society	CI
11/08	Savara Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

25/08	Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP)	AQ
24/08	Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026	BU
20/08	Savara Announces New Employment Inducement Grant	BU
11/08	Savara Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
30/07	Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041	BU
12/06	Savara Announces New Employment Inducement Grant	BU
08/06	Savara Announces Chief Financial and Administrative Officer Transition	BU
27/05	Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference	BU
20/05	Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026	BU
19/05	Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	BU
18/05	Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	BU
12/05	Savara Reports First Quarter Financial Results and Provides Business Update	BU
11/05	Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference	BU
17/04	Savara Announces New Employment Inducement Grant	BU
15/04	Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
14/04	Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference	BU
08/04	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency Has Accepted the MOLBREEVI Marketing Authorisation Application for Autoimmune Pulmonary Alveolar Proteinosis	AQ
07/04	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
30/03	Savara : Corporate Presentation	PU
30/03	Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
13/03	Savara : Corporate Presentation	PU
13/03	Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update	BU
09/03	Savara Provides Regulatory Update on the MOLBREEVI Development Program in Autoimmune Pulmonary Alveolar Proteinosis	AQ
06/03	Savara : Corporate Presentation	PU
06/03	Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU